Cytokines as an important player in the context of CAR-T cell therapy for cancer: Their role in tumor immunomodulation, manufacture, and clinical implications
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cytokines as an important player in the context of CAR-T cell therapy for cancer: Their role in tumor immunomodulation, manufacture, and clinical implications
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-09-12
DOI
10.3389/fimmu.2022.947648
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- IL-6/IFN-γ double knockdown CAR-T cells reduce the release of multiple cytokines from PBMCs in vitro
- (2022) Huihui Zhang et al. Human Vaccines & Immunotherapeutics
- Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment
- (2021) Zhiling Yan et al. Frontiers in Immunology
- The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma
- (2021) Deming Duan et al. Frontiers in Immunology
- Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy
- (2021) Lorenzo Lindo et al. Frontiers in Immunology
- Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment
- (2021) Guangna Liu et al. Cellular & Molecular Immunology
- Engineered Cytokine Signaling to Improve CAR T Cell Effector Function
- (2021) Matthew Bell et al. Frontiers in Immunology
- Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
- (2021) Frederick L. Locke et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preclinical efficacy and safety evaluation of interleukin-6-knockdown CAR-T cells targeting at CD19
- (2021) Hairuo Wen et al. Annals of Translational Medicine
- Oncolytic adenovirus targeting TGF-β enhances anti-tumor responses of mesothelin-targeted chimeric antigen receptor T cell therapy against breast cancer
- (2020) Yuxiang Li et al. CELLULAR IMMUNOLOGY
- Interleukin-23 engineering improves CAR T cell function in solid tumors
- (2020) Xingcong Ma et al. NATURE BIOTECHNOLOGY
- Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma
- (2020) Jennifer N. Brudno et al. NATURE MEDICINE
- Glypican-3–Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma
- (2020) Sai Arun Batra et al. Cancer Immunology Research
- Inhibition of TGF-β-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer
- (2020) Tanja Stüber et al. Journal for ImmunoTherapy of Cancer
- Recent advances in CAR-T cell engineering
- (2020) Ruihao Huang et al. Journal of Hematology & Oncology
- Macrophage, the potential key mediator in CAR-T related CRS
- (2020) Zhaonian Hao et al. Experimental Hematology & Oncology
- IDO Expression in Cancer: Different Compartment, Different Functionality?
- (2020) Annabel Meireson et al. Frontiers in Immunology
- Roles of IFN-γ in tumor progression and regression: a review
- (2020) Dragica Jorgovanovic et al. Biomarker Research
- Cytokine and Chemokine Signals of T-Cell Exclusion in Tumors
- (2020) Yu Zhang et al. Frontiers in Immunology
- Engineering better chimeric antigen receptor T cells
- (2020) Hao Zhang et al. Experimental Hematology & Oncology
- Eradication of neuroblastoma by T cells redirected with an optimized GD2-specific chimeric antigen receptor and interleukin-15
- (2019) Yuhui Chen et al. CLINICAL CANCER RESEARCH
- Tisagenlecleucel CAR-T Cell Therapy in Secondary CNS Lymphoma
- (2019) Matthew J. Frigault et al. BLOOD
- TEMPORARY REMOVAL: IFN-γ: A cytokine at the right time, is in the right place
- (2019) J. Daniel Burke et al. SEMINARS IN IMMUNOLOGY
- Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy
- (2019) Sophia Stock et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- MUC1 as a target for CAR‐T therapy in head and neck squamous cell carinoma
- (2019) Zi Mei et al. Cancer Medicine
- Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia
- (2018) Jiang Cao et al. AMERICAN JOURNAL OF HEMATOLOGY
- GMP CAR-T cell production
- (2018) Adrian P. Gee BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication
- (2018) Christopher C. Kloss et al. MOLECULAR THERAPY
- Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
- (2018) Joseph A. Fraietta et al. NATURE MEDICINE
- Chimeric Antigen Receptor Therapy
- (2018) Carl H. June et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
- (2018) Jae H. Park et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy
- (2018) Noelle Frey et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells
- (2017) Lynsey M. Whilding et al. MOLECULAR THERAPY
- Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer
- (2017) Somala Mohammed et al. MOLECULAR THERAPY
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting
- (2017) Kazuyoshi Takeda et al. Nature Communications
- Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment
- (2017) Oladapo O. Yeku et al. Scientific Reports
- CAR T Cells Releasing IL-18 Convert to T-Bet high FoxO1 low Effectors that Exhibit Augmented Activity against Advanced Solid Tumors
- (2017) Markus Chmielewski et al. Cell Reports
- Toxicities of chimeric antigen receptor T cells: recognition and management
- (2016) Jennifer N. Brudno et al. BLOOD
- Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies
- (2016) Nathan Singh et al. Science Translational Medicine
- CAR-T Cell Therapies From the Transfusion Medicine Perspective
- (2016) Andrew Fesnak et al. TRANSFUSION MEDICINE REVIEWS
- Multiparameter comparative analysis reveals differential impacts of various cytokines on CART cell phenotype and function ex vivo and in vivo
- (2016) Xiao-Jun Xu et al. Oncotarget
- Clinical manufacturing of CAR T cells: foundation of a promising therapy
- (2016) Xiuyan Wang et al. Molecular Therapy-Oncolytics
- IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer
- (2015) K Abiko et al. BRITISH JOURNAL OF CANCER
- TRUCKs: the fourth generation of CARs
- (2015) Markus Chmielewski et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
- (2015) Alfred L. Garfall et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- The two faces of IL-6 in the tumor microenvironment
- (2014) Daniel T. Fisher et al. SEMINARS IN IMMUNOLOGY
- Chronic Inflammation and Cytokines in the Tumor Microenvironment
- (2014) Glauben Landskron et al. Journal of Immunology Research
- Inflammation-induced hepatocellular carcinoma is dependent on CCR5 in mice
- (2013) Neta Barashi et al. HEPATOLOGY
- Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and Immunotherapy
- (2013) Wei Liao et al. IMMUNITY
- Cytokine patterns in patients with cancer: a systematic review
- (2013) Bodo E Lippitz LANCET ONCOLOGY
- Myeloid-Derived Suppressor Cells Interact with Tumors in Terms of Myelopoiesis, Tumorigenesis and Immunosuppression: Thick as Thieves
- (2013) Alexandra Sevko et al. Journal of Cancer
- IL-12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expression
- (2011) M. Chmielewski et al. CANCER RESEARCH
- IL-18 Induces PD-1-Dependent Immunosuppression in Cancer
- (2011) M. Terme et al. CANCER RESEARCH
- Interleukin-2 and Inflammation Induce Distinct Transcriptional Programs that Promote the Differentiation of Effector Cytolytic T Cells
- (2010) Matthew E. Pipkin et al. IMMUNITY
- Interleukin-2 Receptor Signaling: At the Interface between Tolerance and Immunity
- (2010) Thomas R. Malek et al. IMMUNITY
- T-bet and Eomesodermin Are Required for T Cell-Mediated Antitumor Immune Responses
- (2010) Y. Zhu et al. JOURNAL OF IMMUNOLOGY
- Human epithelial ovarian carcinoma cell-derived cytokines cooperatively induce activated CD4+CD25−CD45RA+naïve T cells to express forkhead box protein 3 and exhibit suppressive abilityin vitro
- (2009) Xiaofeng Zhao et al. CANCER SCIENCE
- Tumor Self-Seeding by Circulating Cancer Cells
- (2009) Mi-Young Kim et al. CELL
- IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy
- (2008) C. S. Hinrichs et al. BLOOD
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started